Beskrivelse
2010 (2010-10-01), page S149, XP027316893, ISSN: 1063-4584 [retrieved on 2010-09-29], SCHWARTZ SHERWYN ET AL: "Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.", CURRENT MEDICAL RESEARCH AND OPINION JAN 2011 LNKD- PUBMED:21162697, vol.
27, no.1, January 2011 (2011-01), pages 151-162, XP009150479, ISSN: 1473-4877, LANGE R ET AL: "333 SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol.18, 1 October 2010 (2010-10-01), pages S147-S148, XP027316889, ISSN: 1063-4584 [retrieved on 2010-09-29]
Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/
Krav
IPC-klasse
Fullmektig i Norge:
Org.nummer: 982702887
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2011.04.29, EP 11003508
AFILALO MARC ET AL: "Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study", CLINICAL DRUG INVESTIGATION, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 30, no. 8, 1 August 2010 (2010-08-01) , pages 489-505, XP009148168, ISSN: 1173-2563, DOI: DOI:10.2165/11533440-000000000-00000 (B1)
BJELLAND INGVAR ET AL: "The validity of the Hospital Anxiety and Depression Scale: An updated literature review", JOURNAL OF PSYCHOSOMATIC RESEARCH, vol. 52, no. 2, February 2002 (2002-02), pages 69-77, ISSN: 0022-3999 (B1)
SCHWARTZ SHERWYN ET AL: "Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial.", CURRENT MEDICAL RESEARCH AND OPINION JAN 2011 LNKD- PUBMED:21162697, vol. 27, no. 1, January 2011 (2011-01), pages 151-162, XP009150479, ISSN: 1473-4877 (B1)
KUPERWASSER B ET AL: "337 HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL EXTENSION STUDY", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 18, 1 October 2010 (2010-10-01), page S149, XP027316893, ISSN: 1063-4584 [retrieved on 2010-09-29] (B1)
LANGE R ET AL: "333 SHORT FORM-36 (SF-36) AND EUROQOL-5 DIMENSION (EQ-5D) RESULTS FROM RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDIES OF TAPENTADOL PROLONGED RELEASE (PR) IN PATIENTS WITH MODERATE TO SEVERE CHRONIC NOCICEPTIVE AND NEUROPATHIC PAIN", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 18, 1 October 2010 (2010-10-01), pages S147-S148, XP027316889, ISSN: 1063-4584 [retrieved on 2010-09-29] (B1)
KUPERWASSER B ET AL: "337 EVALUATION OF LONG-TERM TREATMENT WITH TAPENTADOL EXTENDED RELEASE AND OXYCODONE CONTROLLED RELEASE IN PATIENTS WITH CHRONIC LOW BACK OR OSTEOARTHRITIS PAIN: RESULTS FROM PATIENT AND PHYSICIAN GLOBAL ASSESSMENTS AND THE EUROQOL 5 DIMENSION QUESTIONNAIRE", OSTEOARTHRITIS AND CARTILAGE, BAILLIERE TINDALL, LONDON, GB, vol. 17, 1 September 2009 (2009-09-01), page S179, XP026582221, ISSN: 1063-4584, DOI: DOI:10.1016/S1063-4584(09)60359-9 [retrieved on 2009-09-01] (B1)
Statushistorie
| Hovedstatus | Beslutningsdato, detaljstatus |
|---|---|
| Patent opphørt | Ikke betalt årsavgift |
| EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
| EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
|
Dato
Type korrespondanse
Journal beskrivelse
|
|---|
|
Utgående
EP Opphørt for ikke betalt årsavgift (3206)
|
|
Utgående
EP Påminnelse om ikke betalt årsavgift (3331) (PTEP2701693)
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
|
Utgående
EP Batch Varsel om betaling av første årsavgift (3319)
|
|
Utgående
EP Registreringsbrev (3210)
|
|
Innkommende
Søknadsskjema Patent
|
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
| Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
|---|---|---|---|---|
| Årsavgift 12. avg. år (EP) | 2023.04.12 | 3850 | CPA GLOBAL LIMITED | Betalt og godkjent |
| Årsavgift 11. avg. år (EP) | 2022.04.11 | 3500 | CPA GLOBAL LIMITED | Betalt og godkjent |
| Årsavgift 10. avg. år (EP) | 2021.04.09 | 3200 | CPA GLOBAL LIMITED | Betalt og godkjent |
| Årsavgift 9. avg. år (EP) | 2020.04.14 | 2850 | CPA GLOBAL LIMITED | Betalt og godkjent |
| Årsavgift 8. avg. år (EP) | 2019.04.09 | 2550 | CPA GLOBAL LIMITED | Betalt og godkjent |
| Årsavgift 7. avg. år (EP) | 2018.04.10 | 2200 | CPA GLOBAL LIMITED | Betalt og godkjent |
| 31718350 expand_more expand_less | 2017.11.21 | 5500 | Zacco Norway AS | Betalt |
|
Valideringsgebyr EP-patent
5500 = 1 X 5500
|